ClinicalTrials.gg
Not yet recruitingNCT07947420Updated Nov 19, 2026

Effect of Low Intensity Pulsed Ultrasound on Involution of the Uterus Postpartum

An interventional study of Postpartum exercise program and Low intensity pulsed ultrasound in Uterine Involution, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 25 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
25 Years to 40 Years
Sex
Female
01

Study summary

The aim of this study is to determine the effect of low intensity pulsed ultrasound on subinvolution of the uterus postpartum.

Read the detailed description

Low intensity pulsed ultrasound (LIPUS) is a safe and effective treatment for uterine involution. It contributes to uterine contraction after cesarean section, shortens the duration of lochia and relieves postpartum pain, thus decreasing the incidence of poor uterine involution, reducing vaginal bleeding and decreasing fundal height which was assessed using fundal level test. LIPUS can increase the frequency and amplitude of spontaneous contractions of the uterus in postpartum women. Therefore, this study will be conducted to investigate the effect of LIPUS on subinvolution through decreasing the incidence of delayed uterine atony and postpartum hemorrhage in postpartum women whether they had vaginal or cesarean delivery. There is no previous study illustrating the effect of LIPUS on subinvolution by using an objective measurement, so in this study, the effect of LIPUS will be measured using an evaluative ultrasonography. This study will add a new piece of information that maybe helpful for women suffering from this condition and may help the field of physical therapy for women health.

02

Conditions studied

  • Uterine Involution

Keywords

  • uterine subinvolution
  • postpartum
  • low intensity ultrasound
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,965 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postpartum women with uterine subinvolution (delivered vaginally or through caesarean section).
  • All women are regularly lactating.
  • Their age will be ranged from 25 to 40 years old.
  • Their will be ranged from 20 - 30 kg/m².

Exclusion criteria

Exclusion Criteria:

  • History of abdominal surgeries except for cesarean section.
  • Abdominal skin diseases, lesions, injuries, burns or open wounds.
  • Any malignant tumors or fibroids.
  • Coagulation disorders.
  • History of chronic diseases such as diabetes, hypertension, cardiovascular and pulmonary diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Postpartum exercise program group

    The participant will follow a program of postpartum exercises, 30 minutes, 3 sessions / week for 6 weeks.

    Other: Postpartum exercise program

  • Experimental
    Low intensity pulsed ultrasound and postpartum exercise program group

    The participants will receive low intensity pulsed ultrasound with frequency 0.7-1.0 MHz for 30 minutes, 3 sessions / week for 6 weeks, in addition to the same program of postpartum exercises.

    Other: Postpartum exercise program · Device: Low intensity pulsed ultrasound

Interventions

  • OtherPostpartum exercise program

    The postpartum exercise program will begin with 6-minute warm up stretching exercises for hamstrings, hip adductors, gluteal muscles, quadriceps, calves and soleus. The main phase of exercise program will consist of core stabilization exercises, done for 10 repetition and repeated twice / day, total of 30 minutes, 3 sessions / week for 6 weeks. It will include abdominal breathing exercise, bridge exercises and kneeling abdominal exercises.

  • DeviceLow intensity pulsed ultrasound

    The participants will receive therapeutic ultrasound using the following parameters: frequency 0.7-1 MHz, with intensity \<3 W/cm2 for 30 min, 6 hours post vaginal delivery and 24 hours post cesarean section.

06

What researchers measure

Primary outcomes

  1. Uterine involution

    A diagnostic ultrasound device (EDAN, DUS 60, China), with 2.5-MHz convex transducer will be used to trace fundus level and progression of uterine involution before and after the intervention for all participants in both groups.

    Time frame: 6 weeks

  2. Pain Intensity

    Visual analogue scale (VAS) will be used to assess pain intensity. It is a numeric scale, usually represents a horizontal line, 100 mm (10cm) in length, representing the severity of symptoms from 0 "no symptoms" to 10 "very severe symptoms . VAS is a valuable and reliable tool for the documentation of symptom severity, treatment effectiveness.

    Time frame: 6 weeks

07

Study locations

1 site
  • Cairo university
    Tanta, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 20, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947420
Lead sponsor
Cairo University
Responsible party
Alaa Hisham Ibrahim Zamzam (principal investigator, Cairo University) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 20, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Alaa H Ibrahim, Bachelor
Contact
alaahisham197@gmail.com
01019209456
Mahitab M Yosri, PHD
Contact
mahitab.yosri@pt.cu.edu.eg
01222606996
Hossam H Kamel, Professor
study director · Al-Azhar University
Hala M Omara, Professor
study chair · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion